The patient was treated with radiotherapy and temozolomide and remained in remission at nine months post-treatment [9]. Alvarez-Breckenridge et al. identified NTRK fusions (STRN3-NTRK2, WNK2-NTRK2, and BCAN-NTRK1) in three patients with low-grade glioneuronal tumors and reported the first case of successful treatment of a glioneuronal tumor with NTRK inhibition. The gene discussed is WNK2; the disease is mixed neuronal-glial tumor.